Disease tolerance is the ability of the host to reduce the effect of infection on host fitness. Analysis of disease tolerance pathways could provide new approaches for treating infections and other inflammatory diseases. Typically, an initial exposure to bacterial lipopolysaccharide (LPS) induces a state of refractoriness to further LPS challenge (endotoxin tolerance). We found that a first exposure of mice to LPS activated the ligand-operated transcription factor aryl hydrocarbon receptor (AhR) and the hepatic enzyme tryptophan 2,3-dioxygenase, which provided an activating ligand to the former, to downregulate early inflammatory gene expression. However, on LPS rechallenge, AhR engaged in long-term regulation of systemic inflammation only in the presence of indoleamine 2,3-dioxygenase 1 (IDO1). AhR-complex-associated Src kinase activity promoted IDO1 phosphorylation and signalling ability. The resulting endotoxin-tolerant state was found to protect mice against immunopathology in Gram-negative and Gram-positive infections, pointing to a role for AhR in contributing to host fitness.
Although lipopolysaccharide (LPS)-induced proinflammatory molecules are indispensable for counteracting the growth and dissemination of Gram-negative bacteria, overproduction can lead to sepsis syndrome, also known as endotoxin shock. However, a prior exposure to a low level of LPS induces a durable state of cell refractoriness to subsequent LPS challenge, a condition known as endotoxin tolerance [1] [2] [3] [4] . The complex events underlying this phenomenon remain poorly understood, despite a recent resurgence of interest in this effect, which involves multiple downstream effector cells and mechanisms. Endotoxin tolerance, not merely amounting to a shutdown of LPS-induced responses, involves reprogramming of gene expression 5 and chromatin remodelling 6 . The occurrence of endotoxin tolerance has been reported in several disease settings, including sepsis, trauma, surgery, and pancreatitis, underlining its clinical significance. Pharmacologic modulation of LPS-responsive genes to accelerate the onset of endotoxin tolerance would be beneficial in clinical settings dominated by acute hyperinflammatory responses to infection 5 . In addition, endotoxin derived from Gram-negative bacteria is known to have immunomodulatory and allergy-protective potential 7 . In experimental models, the aryl hydrocarbon receptor (AhR), a ligand-operated transcription factor 8, 9 , participates in the transcriptional regulation of several LPS-responsive genes, and AhR-deficient mice are more sensitive to endotoxin shock than wild-type mice 10 . This suggests a crucial function of AhR in modulating the inflammatory response mediated by LPS and Toll-like receptor (TLR)4 signalling 5 . Yet, the nature of the endogenous ligands that drive AhR-regulated gene expression in response to TLR4 activation has been unclear 11 . Also, the potential role of AhR in endotoxin tolerance has never been addressed experimentally. The first step in tryptophan catabolism is the cleavage of the 2,3-double bond of the indole ring of tryptophan 12 . In mammals, this reaction is performed independently by indoleamine 2,3-dioxygenase 1 (IDO1), tryptophan 2,3-dioxygenase (TDO or TDO2; mostly expressed in the liver), and the recently discovered indoleamine 2,3-dioxygenase 2 (IDO2; a paralogue of IDO1). When induced by proinflammatory cytokines 13 , tryptophan degradation by IDO1 yields a series of catabolites-collectively known as kynurenines 14 -that regulate immune homeostasis by acting as AhR ligands and allowing the generation of regulatory T cells [15] [16] [17] , which protect mice from chronic hyperinflammatory responses 18 . Increased plasma kynurenine levels and kynurenine-totryptophan ratios have been found in patients with systemic inflammatory response syndrome, sepsis and septic shock, but the biological significance and prognostic value of these findings have remained uncertain 19 . In the current study we used C57BL/6 wild-type mice, AhR-deficient mice, and mice lacking IDO1, IDO2 or TDO2 to investigate the role of AhR and tryptophan catabolism in primary LPS responsiveness and in the induction of endotoxin tolerance. We found that overreacting responses to primary LPS challenge were mitigated by AhR and TDO2-dependent tryptophan catabolism. Endotoxin tolerance, in contrast, required the combined effects of AhR, IDO1 and the cytokine transforming growth factor-b (TGF-b). The protective, LPS-triggered tolerant state was not restricted to immunopathology induced by LPS or Gram-negative bacteria, in that it also specifically targeted inflammatory cytokine production in a Streptococcus-induced multifocal septic arthritis model.
Endotoxaemia in Ahr
-/-and Tdo2 -/-mice During sepsis, activation of phagocytes leads to tissue damage by migratory neutrophils and overproduction of proinflammatory cytokines, which worsen systemic inflammation and result in haemodynamic changes, multiple organ failure and ultimately death. The synthesis of acute phase proteins occurs in the liver. We investigated the effects of a first, sublethal dose (10 mg per kg, intraperitoneally) of LPS in C57BL/6 wild-type, Ido1
, Tdo2 -/-and Ahr -/-mice (Fig. 1a) . Susceptibility to endotoxaemia was greatly increased in AhR knockout (KO) and TDO2 KO mice with respect to wild-type controls, with limited (IDO1) or no (IDO2) effects of either indoleamine 2,3-dioxygenase deficiency. LPS induced an increase in serum kynurenine-to-tryptophan (Kyn/Trp) ratios, an effect that was selectively negated by Tdo2 deficiency (Fig. 1b) .
Mice of the different genotypes were challenged with a wide range (2.5-80 mg per kg) of LPS doses, to calculate the median lethal dose (LD 50 ) of endotoxin (Fig. 1c) . LD 50 values (mg per kg) varied among the different genotypes, being highest in wild-type (27.3), Ido1 -/-(22.5) and Ido2 -/-(32.1) mice, and considerably lower in Tdo2 -/-(9.7) and Ahr -/-(5.2) mice. Consistent results were obtained using either the IDO1 and IDO2 inhibitor 1-methyltryptophan (1-MT) or the TDO2-selective inhibitor 680C91 (Extended Data Fig. 1a) . LD 50 values varied between inhibitor-treated mice, being considerably higher in 1-MT-treated (22.8) than 680C91-treated (7.2) mice (Extended Data Fig. 1b) . Histopathology of the lungs (Fig. 1d) and liver (Fig. 1e) revealed that inflammation and neutrophil infiltration were most intense in AhR KO and TDO2 KO mice. This suggested that, upon primary LPS challenge, IDO1 and IDO2 may not contribute significantly to protection 20 and that AhR and hepatic TDO2 are, in contrast, functionally important for protection.
Analysis of blood samples from wild-type, Ahr
mice at different times of LPS administration (10 mg per kg) showed a marked increase in plasma concentrations of TNF-a and IL-6 (peaking at 2 h under all conditions, and only marginally declining thereafter in Ahr -/-and Tdo2 -/-mice), IL-1b (peak levels at 6 h, further increasing at 24 h in Ahr -/-and Tdo2 -/-mice), and IL-10 (with high, sustained production only in wild-type and Ido1 -/-mice; Fig. 1f ). Thus, in accordance with previous data in the literature, resistance to primary LPS challenge correlated with an early (2-6 h), yet reversible (24 h), increase in plasma levels of TNF-a, IL-6 and IL-1b-all dysregulated by AhR deficiency 10, 21, 22 -and with a progressive increase in IL-10 (in wild-type and Ido1
-/-mice, as opposed to the stable levels in Ahr -/-and Tdo2 -/-mice). The AhR-and TDO2-dependent induction of IL-10 was crucial in regulating the proinflammatory response to endotoxin in wild-type mice (Extended Data Fig. 2a,b) . Exogenous IL-10 (250 ng per mouse, daily, administered from challenge through day 5) significantly improved survival in both TDO2-and AhR-deficient mice receiving 10 mg per kg LPS on day 0 (Extended Data Fig. 2c ). TGF-b was not detectable under any conditions over the timeframe of observation.
Real-time PCR analysis revealed that, in response to 10 mg per kg LPS, AhR was expressed early (24 h) at the injection site, in peritoneal exudate cells (PECs). No modulation was observed in the liver. Tdo2 was induced in the liver at 6-24 h of LPS injection, whereas no induction was observed in PECs (Fig. 1g) . Also, no induction at all of Ahr and Tdo2 occurred in Tlr4 -/-mice. Protein expressions of AhR, TDO2, IDO1 and IDO2 were assessed at 24 h by immunoblot analysis in PECs and liver cells, demonstrating a positive correlation with the PCR data (Fig. 1h) . Concurrent with the hepatic TDO2 expression was an increase in serum L-kynurenine-to-tryptophan ratios, an effect that was blocked by the TDO2 inhibitor 680C91, but not by Ido1 deficiency (Fig. 1i) .
To ascertain whether AhR expression correlated with functional activity, we measured induction of AhR-mediated gene transcription ex vivo in cells from wild-type mice, treated with 10 mg per kg LPS. Real-time PCR was used to assess transcription of a gene (Cyp1a1) whose promoter contains xenobiotic response elements (Fig. 1j) . Cyp1a1 was induced in PECs and liver cells at 24 h, and this induction was dependent on TDO2 (and not on IDO1) and was restored in TDO2 inhibitortreated mice by L-kynurenine, the first by-product of tryptophan catabolism in the kynurenine pathway and an AhR signalling pathway inducer 16 .
L-kynurenine as an endogenous AhR ligand
The nature of L-kynurenine as an AhR ligand 23 was preliminarily investigated in hepatocytes (which abundantly express the receptor) by binding competition experiments with [ Fig. 2a ). Molecular modelling and docking studies, and dynamics and free-energy calculations entered into a homology model of the PAS-B domain of AhR supported the ability of L-kynurenine to interact with the receptor, identifying Gln 377 as a key residue involved in the effective binding of the ligand (that is, through hydrogen bonds in the bestscoring energetic binding model). This residue was not previously reported as being part of the fingerprint residues necessary for the binding of TCDD to AhR 24 ( Fig. 2b, c) . -/-and Ahr -/-mice to primary LPS challenge. a, Survival data of challenged mice (n 5 10). One of three experiments. *P , 0.05; **P , 0.001 (log-rank test). b, Kyn/Trp ratios. Mean 6 s.d. of three experiments. *P , 0.05; **P , 0.001 (two-tailed Student's t-test). c, Estimation of LD 50 (n 5 10). d, e, Histopathology in lungs and liver, respectively. Scale bar, 100 mm. f, Cytokine measurements (means 6 s.d.) from three experiments (n 5 6; **P , 0.001; two-tailed Student's t-test). g, Gene transcript expressions. Means 6 s.d. (three experiments; **P , 0.001; Shapiro test). PECs, peritoneal exudate cells. h, Immunoblotting data. One experiment of three. i, Kyn/Trp ratios (means 6 s.d. of three experiments). *P , 0.05; **P , 0.001 (two-tailed Student's t-test). j, Cyp1a1 transcript expression; three experiments; **P , 0.001 (Shapiro test).
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To substantiate the in silico data, a mutant AhR receptor was engineered carrying a Gln377Ala mutation (Q377A), and AhR-deficient conventional dendritic cells (cDCs, splenic CD11c 1 CD11b 1 DCs) were reconstituted with wild-type or mutated AhR. Transfection efficiency (about 50%) was similar for the two constructs, as revealed by staining with antibody recognizing both wild-type and mutant AhR on fluorescence-activated cell sorting analysis. No differences in protein half-life (< 8 h) were found in cDCs reconstituted with either wildtype or AhR(Q377A) (Extended Data Fig. 3a, b) . When assayed for Cyp1a1 transcriptional activity in cDCs reconstituted with mutated AhR, L-kynurenine exhibited complete loss of biologic activity, in terms of potency and likely affinity, compared to wild-type receptor-transfected counterparts (Fig. 2d) . In contrast, on stimulation with TCDD, the 50% maximal effective concentration (EC 50 ) value of TCDD was approximately 20-fold lower when cells had been reconstituted with the mutated AhR ( Fig. 2d ), pointing to greater potency and affinity of the ligand for AhR(Q377A). Competition by L-kynurenine for specific binding of [ 3 H]TCDD to cytosolic AhR from reconstituted Ahr -/-DCs allowed for an estimated L-kynurenine IC 50 value of 36.2 mM and of 21.6 mM for K i (Fig. 2e) . Thus L-kynurenine and TCDD bind AhR with distinct affinities and exploit different types of interactions with AhR, either interaction involving a unique set of fingerprints residues necessary for effective binding.
AhR-deficient cDCs reconstituted with wild-type AhR, but not AhR (Q377A), transcriptionally expressed Ido1 (Fig. 2f) , Il10 (Fig. 2g) and Tgfb1 (Fig. 2h ) in a dose-dependent manner in response to L-kynurenine, further underlining the crucial requirement for Gln 377 in the AhRdependent transcriptional activity in our setting. Cotransfection of Q377A and wild-type AhR (but not a mock control) resulted in Ido1, Il10 and Tgfb1 transcription ( Fig. 2f-h ), indicating that the mutant AhR did not interfere with wild-type AhR function. Altogether, these data supported the binding mode of L-kynurenine to AhR as predicted by docking studies, and they explained the AhR requirement for kynurenine induction of Cyp1a1 transcription in PECs and liver cells (Fig. 2i) .
When 200 mg per kg L-kynurenine (first-order elimination kinetics,
; resulting in physiologically attainable concentrations in the low micromolar range) was administered to mice receiving 10 mg per kg LPS and the TDO2 inhibitor, all mice survived challenge, and this effect was negated by AhR deficiency (Fig. 2j) . Overall, these data confirmed the crucial role of TDO2-dependent tryptophan catabolism in the activation of AhR, which is, in turn, necessary for downregulating inflammatory gene expression in primary endotoxaemia. These data were also consistent with previous data in a different setting showing that L-kynurenine requires AhR in the absence of functional TDO2 25 .
IDO1, AhR and TGF-b in LPS tolerance
Next we examined the effect of high-dose LPS challenge in wild-type, IDO1-deficient or IDO2-deficient mice surviving a primary dose of 10 mg per kg LPS administered 1 week earlier. Primed mice, as well as sham-tolerized controls of the different genotypes, received 40 mg per kg LPS intraperitoneally, to be monitored for mortality parameters (Fig. 3a) . Only LPS-primed wild-type mice and Ido2 -/-mice survived rechallenge beyond the 30-day observation period (P , 0.0001 vs Ido1 -/-and unprimed wild-type mice), as opposed to the rapid onset of a lethal shock in the other groups, whose median survival times were very similar (that is, 24-48 h). Notably, under those conditions of primary LPS challenge (10 mg per kg), the LD 50 of LPS-primed (that is, tolerant) wild-type mice consistently exceeded 80 mg per kg, when estimated 1 week after a first exposure to LPS. The LD 50 values of primed Ido1 -/-and unprimed wild-type mice were similar (27.1 and 33.9 mg per kg, respectively; Fig. 3b ). Histopathology of lungs and liver showed that, at 48 h of rechallenge with 40 mg per kg LPS, inflammation and neutrophil infiltration were similar in LPS-primed Ido1 -/-mice and in IDO1-competent, unprimed controls (Fig. 3c, d) .
After LPS rechallenge, increased transcriptional expression of Ido1 and increased protein levels were demonstrable in splenic CD11c 
CD11b
1 DCs (usually referred to as conventional DCs, or cDCs) and only marginally in peritoneal macrophages, and not at all in plasmacytoid DCs (pDCs) and peritoneal neutrophils (Extended Data Fig. 4a, b) . LPS-primed wild-type and Ido1
-/-cDCs promptly upregulated Ahr transcription upon LPS restimulation, yet this translated into enhanced AhR-dependent transcriptional activity only in IDO1-competent DCs, 
three experiments. **P , 0.001 (Shapiro test). j, Survival curves of variously treated mice (n 5 10; one of three experiments). **P , 0.001 (log-rank test).
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suggesting a necessary role for IDO1-dependent tryptophan catabolism in AhR-dependent gene transcription under those conditions of LPS rechallenge (Extended Data Fig. 4c) . Likewise, the AhR requirement for endotoxin tolerance was demonstrated by the use of the specific antagonist, CH-223191 (Fig. 3e) .
We also explored whether Ahr -/-mice could be tolerized by sublethal LPS amounts. The highest LPS dosage resisted by naive Ahr -/-mice (that is, 0.5 mg per kg) would still confer some degree of endotoxin tolerance on wild-type mice but not on AhR-deficient mice (Extended Data Fig. 5a ). In contrast, TDO2 was not required for endotoxin tolerance, because inhibition of TDO2 at the time of LPS rechallenge with its selective inhibitor had no effects, and Tdo2 -/-survivors of a primary LPS challenge would resist rechallenge to an extent comparable to primed wild-type controls (Extended Data Fig. 5b) . Thus endotoxin tolerance, once established, did not require functional TDO2, but was dependent on the combined effects of IDO1 and AhR.
The early pattern of cytokine production by LPS-tolerant mice (at 2-24 h of rechallenge) was characterized by progressively decreasing levels of circulating TNF-a and IL-6, but sustained production of IL-10 and the appearance of circulating TGF-b, contingent on IDO1 (Fig. 3f) . The cytokine secretion pattern of endotoxin-tolerant wild-type mice was in marked contrast with that of Ido1 -/-mice, which resembled the cytokine secretion profile of unprimed wild-type controls (Fig. 3f) . TGFb was required for endotoxin tolerance because neutralization of TGF-b at the time of LPS rechallenge ablated protection (Fig. 3g) . Increased serum tryptophan-to-kynurenine ratios were observed, on rechallenge, only in IDO1-competent mice (Fig. 3h) .
In vivo, we investigated whether supplementary L-kynurenine, similar to what was observed in the primary challenge of TDO2 KO mice with LPS, would be sufficient alone to reinstall tolerance in otherwise susceptible LPS-primed Ido1 -/-mice. We treated mice with L-kynurenine at 6 h of LPS rechallenge (Fig. 3i) . L-kynurenine failed to restore tolerance in the absence of IDO1, and there occurred a marked defect in TGF-b production in those mice, indicating that IDO1 was required for circulating TGF-b production. Additional IDO1 functions, beside kynurenine production, might thus be required for establishing a fully protective endotoxin-tolerant state.
AhR-dependent IDO1 phosphorylation
IDO1-dependent effects include non-enzymic functions, namely intracellular signalling events that, initiated by phosphorylation of specific domains in the enzyme, are involved in reprogramming gene expression and in the induction of a stably regulatory phenotype in splenic pDCs 26 . Such polarized, tolerogenic pDCs produce less IL-6, but they start producing TGF-b in response to TLR signalling 27 or to TGF-b in vitro 28 . Because of the failure of supplementary L-kynurenine to confer significant endotoxin tolerance on LPS-primed Ido1 -/-mice, we investigated whether IDO1-mediated signalling contributed to LPS tolerance, and in particular, whether IDO1 phosphorylation occurred in LPS-primed, IDO1-competent mice on rechallenge in vivo with LPS. We found that IDO1 phosphorylation could be detected under ex vivo conditions, in isolated spleen cells mostly expressing the CD11c marker, at 15 min of LPS rechallenge in vivo (Fig. 4a, b) . Notably, IDO1 phosphorylation was not detected in the spleens of IDO1 KO mice. In accordance with the ex vivo data, AhR-dependent IDO1 phosphorylation could also be demonstrated in an in vitro model system using LPS-primed, IDO1-competent CD11c
1 DCs on rechallenge with LPS (Fig. 4c) .
To gain preliminary insight into the nature of the kinase responsible for the effect, we searched cDC gene expression profiles in public data sets, focusing on Src kinases known to mediate tyrosine-phosphorylation of intracellular target proteins. Profile analysis indicated that, among several possibilities including Sykb, Blk, Frk, Zap70, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes1 and Csk, the most widely represented kinase in mouse LPS-treated cDCs was the product of Src (Extended Data Fig. 6a, b) . Src kinase activity is triggered by AhR activation 29, 30 , resulting in autophosphorylation and phosphorylation of target proteins 31 . Early, Srcdependent phosphorylation of IDO1 in primed cDCs occurred in response to LPS, and inhibition of Src kinase using a selective inhibitor, PP2 (but not its inactive analogue, PP3) negated IDO1 phosphorylation in LPS-primed cDCs re-exposed to LPS (Fig. 4c) . Also, Src activity required AhR (Fig. 4d) , which was necessary for TGF-b production (Fig. 4e) . Overall, these data indicated that, in endotoxin tolerance, AhR-associated Src activity is responsible for IDO1 phosphorylation and TGF-b production by IDO1-competent cDCs.
LPS tolerance prevention of immunopathology
TLR4 and TLR2 activate innate immune cells in response to Gramnegative and Gram-positive bacteria, respectively. We analysed the impact of endotoxin tolerance on acute infection with LPS-expressing Salmonella enterica Typhimurium (S. Typhimurium, which exploits intestinal inflammation for pathogenicity 32 ; Fig. 5 ), as well as on group B Streptococcus (GBS)-induced multifocal septic arthritis, a condition in which functional TLR2 signalling is necessary for attenuating the severity ) and IDO2-deficient (prIdo2 -/-) mice after rechallenge. n 5 8-10; one experiment of three. **P , 0.001; log-rank test. b, Endotoxin LD 50 in tolerized mice. n 5 10. c, d, Histopathology in lungs and liver, respectively; scale bar, 100 mm. One experiment of two. e, Survival of variously treated mice (n 5 10; one of three experiments). **P , 0.001 (log-rank test). f, Cytokine measurements (mean 6 s.d. of three experiments; n 5 6). **P , 0.001 (two-tailed Student's t-test). g, Neutralization of TGF-b upon LPS rechallenge (n 5 10). Three experiments (mean 6 s.d.); **P , 0.001 (log-rank test). h, Kyn/Trp ratios (mean 6 s.d. of three experiments). **P , 0.001 (two-tailed Student's t-test). i, Survival of variously treated mice. n 5 8-10; one experiment of three. **P , 0.001 (log-rank test).
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of group B streptococcal disease 33 ( Fig. 6 ). In the Salmonella model, both clinical and serological data (Fig. 5a-c) , as well as histopathology (Fig. 5d, e) , provided evidence for reduced inflammatory pathology in LPS-tolerant mice, which was confirmed by lower levels of IL-1b and TNF-a in caecum cell supernatants (Extended Data Fig. 7a) . Moreover, higher levels of IL-10 and TGF-b were found in those mice, in which Foxp3 expression in mesenteric lymph nodes was enhanced, as opposed to Rorc expression (Extended Data Fig. 7a) . A protective role for AhR and IDO1 could also be demonstrated in naive mice (Extended Data Fig. 8a-c) . On assessing the role of endotoxin tolerance in group B Streptococcus-induced septic arthritis, LPS-tolerant mice were infected intravenously with type IV group B streptococci, and disease severity was monitored by assessing survival rates (Fig. 6a) , clinical scores of arthritis (Fig. 6b) , bacterial burden (Fig. 6c), histopathology (Fig. 6d) , and proinflammatory cytokine production (Fig. 6e ). An overall strongly protective effect of LPS tolerance was observed against Streptococcusinduced immunopathology (Extended Data Fig. 9) , and again, a protective role for AhR and IDO1 could also be demonstrated in naive mice (Extended Data Fig. 10a-c) .
Discussion
Several considerations may apply to our current findings. First, our data indicate that, although the class of an immune response is tailored to fit the invading pathogen, its regulation is primarily tailored to fit the tissue in which the response occurs 34, 35 . Second, endotoxin tolerance can be seen as a form of protective 36 or infectious 37 tolerance, whereby the host organism protects itself from infectious diseases by reducing the negative impact of infections on host fitness, an ability epitomized in ref. 38 as ''disease tolerance''. Whereas disease resistance aims at reducing or eliminating infection, disease tolerance is confirmed here to imply an ability to reduce the impact of infection on host fitness. Third, the IDO1 mechanism seems to have been selected through phylogenesis primarily to prevent overreacting responses to TLR-recognized pathogen-associated molecular patterns 39 , and only later did it become involved in the response to T-cell receptor-recognized antigen 15, 26, [40] [41] [42] [43] . AhR, in turn, which has a role in regulatory T-cell generation 17 , is presumed to have evolved from invertebrates, where it served a ligandindependent role in normal development processes. Evolution of the receptor in vertebrates resulted in the ability to bind structurally different ligands, including xenobiotics and microbiota-derived catabolites 44 . Considering the inability of invertebrate AhR homologues to bind dioxins, the adaptive role of the AhR to act as a regulator of xenobioticmetabolizing enzymes may have been a vertebrate innovation, to later 
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acquire an additional immune regulatory role by coevolutive pressure in mammals by IDO1 and regulatory T cells [41] [42] [43] [44] . Although Ahr -/-mice have already been described as manifesting increased susceptibility to endotoxaemia 10 , our data on the respective inabilities of TDO2 KO and IDO1 KO mice to mount protective responses to LPS challenge and rechallenge may be the first to document uncompensated immune deficits in those mice. AhR would, indeed, engage in the long-term regulation of systemic, TLR-triggered inflammation through IDO1, resulting in the onset of a fully protective endotoxin-tolerant state, as exemplified by the Salmonella infection model. However, it is possible that the immunoregulatory effects of tryptophan catabolism represent a generalized phenomenon in infection and infection-related pathology 45, 46 . Our findings in the Streptococcus-induced septic arthritis model demonstrate that endotoxin tolerance does not prevent the early events in protective TLR2 signalling and that it may, in fact, accelerate the later onset of the host's control over immunologically mediated local and systemic disease. This would suggest that endotoxin tolerance helps to control specific, inflammasome-mediated effects of bacterial infection 47 .
Interfering with the trade-offs that the defence systems in both pathogens and their hosts impose on host fitness could ultimately help to selectively enhance pathways responsible for strong and rapid inflammatory responses that lead to effective pathogen clearance, yet do not involve immunopathology 48 . Our current data may pave the way to new therapeutic options in infectious diseases via control of hostpathogen interactions. Druggable candidate targets in those interactions include sensors of pathogen presence (such as TLRs), alterations of host metabolism (including tryptophan catabolism) and environmentresponsive receptors, of which AhR is a prototypical example.
METHODS SUMMARY
All in vivo studies were in compliance with National (Italian Parliament DL 116/ 92) and Perugia University Animal Care and Use Committee guidelines, and the overall study was approved by the Bioethics Committee of the University of Perugia. LPS LD 50 values for each mouse genotype were calculated by curve-fitting (r 2 . 0.96-0.99) and data are from one experiment representative of two or three. In tolerance experiments, mice were injected intraperitoneally with a first dose of LPS (10 mg per kg) and, after 6 days, rechallenged with 40 mg per kg LPS. Determination Real-time PCR with reverse transcription (for mouse genes Ido1, Ido2, Tdo2, AhR, Il10, Tgfb1 and Gapdh) analyses were carried out as described previously 28 , and data are presented as normalized transcript expression in the samples relative to normalized transcript expression in control cultures. For molecular modelling, a multiple alignment between the sequences of PAS-B mAhR (residues 278-384) and PAS-B HIF-2a was generated according to the sequence alignment suggested in ref. 24 . Phosphorylation of IDO1 ex vivo was examined in total splenocytes isolated from wild-type mice, either unprimed or primed in vivo with LPS (10 mg per kg), with or without rechallenge with 40 mg per kg LPS on day 7 of priming. For examining expression of tyrosine kinases in mouse myeloid dendritic cells, we retrieved seven data sets of mouse myeloid dendritic cells from Gene Expression Omnibus, containing information about treatment with LPS and gene expression data obtained with Affymetrix Mouse Genome 430 2.0 arrays.
Online Content Any additional Methods, Extended Data display items and Source Data are available in the online version of the paper; references unique to these sections appear only in the online paper. -/-) mice were originated and bred in H. Funakoshi's laboratory (Center for Advanced Research and Education, Asahikawa Medical University, Japan). All other mice were bred at the animal facility of the University of Perugia, according to the University of Perugia Animal Care and Use Committee guidelines. All animal studies were approved by the Bioethics Committee of the University of Perugia. LPS-induced endotoxaemia tolerance and treatments. In the induction of primary endotoxaemia, mice of the different genotypes were randomly grouped (10 per group) and injected intraperitoneally with different doses of LPS (in a final volume of 200 ml; Sigma #055:B5). LD 50 values for each genotype were calculated by curve fitting (r 2 . 0.96-0.99) and data are from one experiment representative of two (Fig. 1c) or three (Fig. 3b) . In the tolerance experiments, mice were injected intraperitoneally with a first dose of LPS (10 mg per kg) and, after 6 days, rechallenged with 40 mg per kg LPS. Groups of mice received neutralizing antibodies to IL-10 (200 mg per mouse) or TGF-b (11D1; 100 mg per mouse), or recombinant IL-10 (250 ng per mouse), isotype-matched antibodies serving as control treatments. 1-MT (5 mg per mouse; D,L racemic mixture; Sigma) was administered intraperitoneally, and 680C91 (5 mg per kg; R&D Systems) was administered by oral gavage 3 h before LPS administration and then for three consecutive days. CH-223191 (10 mg per kg) was administered by oral gavage starting one day after the first LPS administration and then daily up to LPS rechallenge. Vehicle-treated groups were used as controls. Mice was checked for mortality and autopsied every 12 h for 7 days. Reagents. Rabbit monoclonal anti-mouse IDO1 antibody (cv152) was as described 18 and so was the rabbit polyclonal anti-phospho-IDO1 (anti-pIDO1) 28 . Rabbit antimouse IDO2 (unrecognizing IDO1 epitopes) was raised in our laboratory to an IDO2-specific synthetic peptide (GLKALVQ, GMEAIRQHSRDT, ISAATRARSR GLTNPSPHA) and purified by affinity chromatography. The following antibodies were also used, anti-mouse AhR (R&D Systems and Abcam), anti-mouse TDO2 (a gift from C. L. Miller, Johns Hopkins University, Baltimore, MD), anti-mouse Src and Phospho-Src Family (Tyr416; Cell Signaling), and anti-mouse b-tubulin (SigmaAldrich). The Src inhibitor PP2 and its negative control, PP3, were from Tocris Bioscience. Isolation of macrophages, neutrophils and dendritic cells, and treatments. Mouse peritoneal macrophages were collected from euthanized animals, and purified according to standard procedures. Cells were .99% CD11b 1 , .99% F480 1 , ,0.1% CD3 1 , ,0.1% B220
1
. Neutrophils were isolated from the peritoneal cavity via biotin-labelled anti-Ly6G, by magnetic separation using anti-biotin magnetic beads according to manufacturer's instructions (Miltenyi Biotec). Neutrophils were defined as being CD11b high Ly6G high . Splenic DCs were purified using CD11c MicroBeads (Miltenyi Biotec) in the presence of EDTA to disrupt DC-T-cell complexes. Cells were .99% CD11c 1 , and 1-5% B220 1 cells. DC populations were further fractionated according to CD8 or mPDCA-1 expression to obtain purified CD8 -DCs (cDCs) or mPDCA-1 1 pDCs, by means of selective MicroBeads (Miltenyi Biotec). In accordance with our previous data 15, 28 , the CD8 -fraction was 45% CD4 1 and typically contained ,0.5% contaminating CD8 1 cells, whereas .95% of the mPDCA-1 1 cells were also positive on 120G86 antibody staining. For in vitro studies, cDCs (10 6 cells per well in 24-well plates) were cultured for 24 h with medium or with LPS (0.5 mg ml
21
; on first LPS exposure); when indicated, they were washed and restimulated for an additional 6-24 h with LPS (1 mg ml
). For TGF-b neutralization, cDCs were incubated with 1D11 monoclonal antibody (40 mg ml 21 ). In specific in vitro experiments, PP2 (5 mM) or PP3 (5 mM) were added 1 h before LPS treatment. Real-time RT-PCR. Real-time PCR with reverse transcription (real-time RT-PCR) (for mouse Ido1, Ido2, Tdo2, AhR, Il10, Tgfb1 and Gapdh) analyses were carried out as described 28 , using primers listed in Supplementary Information Table 1 . Liver homogenate was used as a positive control for expression of Tdo2, Ido2, Ahr, and Cyp1A1. RT-PCR data were calculated as the ratio of gene to Gapdh expression by the relative quantification method (DDC t ; means 6 s.d. of triplicate determination), and data are presented as normalized transcript expression in the samples relative to normalized transcript expression in control cultures (in which fold change 5 1; dotted line). ELISA. Mouse cytokines (IL-6, IL-1b, IL-10, TNF-a, TGF-b1, and IL-17A) were measured in serum or culture supernatants by ELISA using specific kits (R&D Systems and Abnova Corporation) or previously described reagents and procedures 28, 49 . The detection limits (pg ml
) of the assays were 2 for IL-6, IL-10, IL-1b and IL-17A, and 15 for TGF-b1.
